Impact of 18F-FDG PET/CT with retrograde filling of the urinary bladder in patients with suspected pelvic malignancies

Journal of Nuclear Medicine Technology

Volumn 38, Issue 3, 2010, Pages 128-137

  Vicente, Ana Maria Garcia ^a   Castrejón, Angel Soriano ^a   Muñoz, Azahara Palomar ^a   Woll, Patrick Pilkington ^a   García, Alicia Nuñez ^a  

^a Hospital General   (Spain)

Author keywords

Pelvic; PET CT; Retrograde bladder filling

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; BLADDER FILLING; BLADDER WALL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GYNECOLOGIC CANCER; HISTOPATHOLOGY; HUMAN; MALE; PELVIS TUMOR; POSITRON EMISSION TOMOGRAPHY; RECTUM CANCER; RETROGRADE BLADDER IRRIGATION; UROGENITAL TRACT TUMOR; ARTIFACT; BLADDER; CLINICAL TRIAL; LAVAGE; METHODOLOGY; MIDDLE AGED; RADIOGRAPHY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; ARTIFACTS; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; PELVIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; THERAPEUTIC IRRIGATION; TOMOGRAPHY, X-RAY COMPUTED; URINARY BLADDER;

EID: 79953236850     PISSN: 00914916     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnmt.109.074146     Document Type: Article

References (31)

1. Schöder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004;34:274-292.
2. Hain SF, Maisey MN. Positron emission tomography for urological tumors. BJU Int. 2003;92:159-164.
3. Kumar R, Zhuang H, Alavi A. PET in the management of urologic malignancies. Radiol Clin North Am. 2004;42:1141-1153.
4. Shvarts O, Han K, Seltzer M, Pantuck AJ, Belldegrun AS. Positron emission tomography in urologic oncology. Cancer Control. 2002;9:335-342.
5. Cook GJR. Artifacts and normal variants in whole-body PET images. In: Valk PE, Bailey DL, Townsend DW, Maisey MN, eds. Positron Emission Tomography: Basic Science and Clinical Practice. London, U.K.: Springer-Verlag; 2003:495-505.
6. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ confined prostate cancer. Urology. 2001;57:108-111.
7. Janzen NK, Laifer-Narin S, Han K, et al. Emerging technologies in uroradiologic imaging. Urol Oncol. 2003;21:317-326.
8. 18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med. 1978;19:1154-1161.
9. Kundra V, Silverman PM. Imaging in the diagnosis, staging and follow-up of cancer of the urinary bladder. AJR. 2003;180:1045-1054.
10. 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors. J Nucl Med. 2003;44:353-358.
11. Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med. 1997;24:615-620.
12. Leisure GP, Vesselle HJ, Faulhaber PF, O'Donnell JK, Adler LP, Miraldi F. Technical improvements in fluorine-18-FDG PET imaging of the abdomen and pelvis. J Nucl Med Technol. 1997;25:115-119.
13. Vesselle HJ, Miraldi FD. FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. Radiographics. 1998;18:805-823.
14. Miraldi F, Vesselle H, Faulhaber PF, Adler LP, Leisure GP. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med. 1998;23:3-7.
15. 18F-FDG PET in abdominopelvic malignancies. J Nucl Med. 2006;47:1803-1807.
16. Sugawara Y, Eisbruch A, Kosuda S, Recker BE, Kison PV, Wahl RL. Evaluation of FDG PET in patients with cervical cancer. J Nucl Med. 1999;40:1125-1131.
17. Grab D, Flock F, Stohr I, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol. 2000;77:454-459.
18. Flamen P, Stroobants S, Van Cutsem E, et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol. 1999;17:894-901.
19. Casey MJ, Gupta NC, Muths CK. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol. 1994;53:331-338.
20. 18F]FDG). Gynecol Oncol. 1993;51:197-204.
21. 18F-FDG-PET) in the diagnosis of recurrence and lymph node metastasis of cervical cancer. Oncol Rep. 2000;7: 1261-1264.
22. Umesaki N, Tanaka T, Miyama M, et al. Early diagnosis and evaluation of therapy in postoperative recurrent cervical cancers by positron emission tomography. Oncol Rep. 2000;7:53-56.
23. Lin WY, Hung G, Tsai SC. Pitfall of FDG-PET image interpretation: accumulation of FDG in the dependent area of the urinary bladder after bladder irrigation-the usefulness of the prone position. Clin Nucl Med. 2005;30:638-639.
24. Lin WY, Wang KB, Tsai SC, Sun SS. Unexpected accumulation of F-18 FDG in the urinary bladder after bladder irrigation and retrograde filling with sterile saline: a possible pitfall in PET examination. Clin Nucl Med. 2009;34:560-563.
25. Moran JK, Lee HB, Blaufox MD. Optimization of urinary FDG excretion during PET imaging. J Nucl Med. 1999;40:1352-1357.
26. Purcell DD, Coakley FV, Franc BL, Hawkins RA, Boddington SE, Yeh BM. Anterior layering of excreted F-18 FDG in the bladder on PET/CT: frequency and cause. AJR. 2007;189:W96-W99.
27. Beyer T, Antoch G, Müller S, et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med. 2004;45(suppl 1):25S-35S.
28. Zhang J, Gerst S, Lefkowitz RA, et al. Imaging of bladder cancer. Radiol Clin North Am. 2007;45:183-205.
29. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med. 2007;48:764-770.
30. Wahl RL. Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. J Nucl Med. 2004;45(suppl 1):82S-95S.
31. Heiba SI, Raphael B, Castellon I, et al. PET/CT image fusion error due to urinary bladder filling changes: consequence and correction. Ann Nucl Med. 2009; 23:739-744.